NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 883.2 DKK | +0.07% |
|
+1.16% | +26.51% |
| May. 10 | Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows | RE |
| May. 10 | India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 568B | ||||||
| 684B | ||||||
| 361B | ||||||
| 329B | ||||||
| 284B | ||||||
| 240B |
- Stock Market
- Equities
- NOVO B Stock
- Charts Novo Nordisk A/S
- Sector Chart